Regeneron acquired 23andMe for $256M, gaining 15M DNA profiles to enhance R&D. Find out why REGN stock is a Buy.

The Motley Fool has positions in and recommends Regeneron Pharmaceuticals. The Motley Fool recommends GSK. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the ...

Genetic testing company 23andMe had 15 million consumers who turned to them to learn more about their ancestry and understand their disposition to diseases.

Analysts maintain a generally positive outlook on Regeneron’s future prospects, despite the near-term challenges. The consensus view suggests ... provide a clearer picture of investment ...

Bayer A.G. ( OTCPK:BAYZF) ( OTCPK:BAYRY) said that an advisory panel of the European Medicines Agency (EMA), endorsed the ...

In the latest episode of Touching Base, we discuss big news in CRISPR along with updates in the business side of biotech.

A trader works during the closing bell, on the floor at the New York Stock Exchange (NYSE) in New York City, U.S., May 19, 2025. REUTERS/Jeenah Moon/File Photo Wall Street surged on Tuesday as ...

Google said the Veo 4 video model will support native audio generation to add background sounds and dialogues.

Global growth is projected at –4.9 percent in 2020, 1.9 percentage points below the April 2020 World Economic Outlook (WEO) forecast. The COVID-19 pandemic has had a more negative impact on activity ...

Amid exceptional uncertainty, the global economy is projected to grow 5.5 percent in 2021 and 4.2 percent in 2022. The 2021 forecast is revised up 0.3 percentage point relative to the previous ...

Forbes contributors publish independent expert analyses and insights. Lars Daniel covers digital evidence and forensics in life and law.